If you typed Endpoints LatAm into a search box, you are probably building a CRO or site shortlist for Panama. This article uses only what is public about Endpoints LatAm (www.endpoints.site) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What Endpoints LatAm publishes
Endpoints LatAm describes itself as a Panama-based clinical research site network serving sponsors, CROs and NGOs, with centers in Panama, Colombia and Guatemala and expansion across Latin America.
Endpoints LatAm vs bioaccess®
| Dimension | Endpoints LatAm | bioaccess® |
|---|---|---|
| Core focus | Multi-country clinical site network | First-in-human and early feasibility studies for medical devices |
| Geography | See provider site | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If you need access to a multi-country research site network in Latin America, Endpoints LatAm’s published services match.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO or site on your list, including Endpoints LatAm, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
For the local regulatory path, see CRO in Panama. Other Latin American CROs are compared in the guide to first-in-human device CROs in Latin America and on the bioaccess® compare hub.
Ready to compare a proposal? Request a first-in-human study proposal.
Facts from the Endpoints LatAm public pages and registries linked above, reviewed for bioaccess® competitive research (Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.
Leave a Reply